Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Treatment plans are customized based on individual goals, medical history, and response to the medication
Compounded tirzepatide is supplied outside the FDA-approved manufacturing supply chain and should only be used with oversight from a licensed clinician
*Mazdutide has received NMPA approval for two indications: First Indication: as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of: BMI 28 kg/m (obesity)
an FDA-approved active ingredient that works directly on the central nervous system by activating melanocortin receptors in the brain, unlike approaches that target the vascular system
Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters
US$ 28.84
US$ 24.12
US$ 20.28
US$ 28.32
US$ 21.06
US$ 27.63
US$ 23.09
